vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and DYNEX CAPITAL INC (DX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $43.5M, roughly 1.8× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs -16.8%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

BIOX vs DX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.8× larger
BIOX
$77.6M
$43.5M
DX
Growing faster (revenue YoY)
DX
DX
+548.1% gap
DX
531.3%
-16.8%
BIOX
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
DX
DX
Revenue
$77.6M
$43.5M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
Revenue YoY
-16.8%
531.3%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$1.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
DX
DX
Q4 25
$43.5M
Q3 25
$77.6M
$30.6M
Q2 25
$23.1M
Q1 25
$60.6M
$17.1M
Q4 24
$98.8M
Q3 24
$93.3M
Q1 24
$84.0M
$-3.2M
Q4 23
$140.2M
Net Profit
BIOX
BIOX
DX
DX
Q4 25
Q3 25
$-7.4M
$150.4M
Q2 25
$-13.6M
Q1 25
$-1.6M
$-3.1M
Q4 24
$605.2K
Q3 24
$-6.2M
Q1 24
$9.8M
$40.1M
Q4 23
$1.2M
Gross Margin
BIOX
BIOX
DX
DX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q1 24
50.8%
Q4 23
36.7%
Operating Margin
BIOX
BIOX
DX
DX
Q4 25
Q3 25
9.3%
Q2 25
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q1 24
15.7%
Q4 23
12.0%
Net Margin
BIOX
BIOX
DX
DX
Q4 25
Q3 25
-9.6%
491.3%
Q2 25
-58.8%
Q1 25
-2.6%
-18.0%
Q4 24
0.6%
Q3 24
-6.6%
Q1 24
11.6%
-1256.8%
Q4 23
0.9%
EPS (diluted)
BIOX
BIOX
DX
DX
Q4 25
$1.59
Q3 25
$-0.12
$1.08
Q2 25
$-0.14
Q1 25
$-0.02
$-0.06
Q4 24
$0.00
Q3 24
$-0.10
Q1 24
$0.14
$0.64
Q4 23
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
DX
DX
Cash + ST InvestmentsLiquidity on hand
$15.5M
$531.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$2.5B
Total Assets
$734.9M
$17.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
DX
DX
Q4 25
$531.0M
Q3 25
$15.5M
$491.0M
Q2 25
$387.5M
Q1 25
$38.5M
$327.4M
Q4 24
$29.2M
Q3 24
$32.3M
Q1 24
$16.4M
$295.7M
Q4 23
$24.4M
Stockholders' Equity
BIOX
BIOX
DX
DX
Q4 25
$2.5B
Q3 25
$288.3M
$2.0B
Q2 25
$1.6B
Q1 25
$345.0M
$1.4B
Q4 24
$346.3M
Q3 24
$346.0M
Q1 24
$348.5M
$958.5M
Q4 23
$335.3M
Total Assets
BIOX
BIOX
DX
DX
Q4 25
$17.3B
Q3 25
$734.9M
$14.2B
Q2 25
$11.3B
Q1 25
$798.2M
$9.0B
Q4 24
$835.2M
Q3 24
$827.3M
Q1 24
$836.1M
$6.3B
Q4 23
$819.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
DX
DX
Operating Cash FlowLast quarter
$14.4M
$120.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
DX
DX
Q4 25
$120.8M
Q3 25
$14.4M
$68.3M
Q2 25
$31.9M
Q1 25
$23.3M
$6.4M
Q4 24
$-5.4M
Q3 24
$5.2M
Q1 24
$-17.4M
$-17.1M
Q4 23
$21.1M
Cash Conversion
BIOX
BIOX
DX
DX
Q4 25
Q3 25
0.45×
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q1 24
-1.78×
-0.43×
Q4 23
17.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons